Orient Pharma Co., Ltd.

As of June 30, 2026, Orient Pharma Co., Ltd. carries a market capitalization of 6.33B, placing it among publicly traded companies globally. Its enterprise value stands at 5.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Orient Pharma Co., Ltd.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Orient Pharma Co., Ltd. has 243.04M shares outstanding.

As of June 30, 2026, Orient Pharma Co., Ltd. trades at a trailing price-to-earnings ratio of 65.20. The price-to-sales ratio is 8.27, and the price-to-book ratio stands at 2.38.

As of June 30, 2026, Orient Pharma Co., Ltd. trades at an EV/EBITDA multiple of 30.93 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 47.64 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Orient Pharma Co., Ltd. trades at an EV/FCF ratio of 86.85, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.94B versus a market cap of 6.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Orient Pharma Co., Ltd. maintains a current ratio of 7.39, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.13, indicating elevated leverage, while an interest coverage ratio of 116.53 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Orient Pharma Co., Ltd. posted a return on equity (ROE) of 3.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.32 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.23, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.47, useful for judging operating efficiency across full business cycles. The company generates approximately 3.58M in revenue per employee across its workforce of 212.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.07 indicates how many times Orient Pharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Orient Pharma Co., Ltd. recorded 32.63M in income tax expense. That works out to an effective tax rate of 25.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 128.78M, leaving 96.15M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Orient Pharma Co., Ltd.'s stock has declined approximately 12.71% over the past 52 weeks. The 50-day moving average sits at 24.26, while the 200-day moving average is 25.32.

Over the twelve months ended June 30, 2026, Orient Pharma Co., Ltd. generated 758.30M in revenue and converted that into 96.15M in net income, yielding earnings per share of 0.40. EBITDA reached 191.93M, while operating income came in at 132.97M.

As of June 30, 2026, Orient Pharma Co., Ltd. holds 585.05M in cash and equivalents against 189.61M in total debt, resulting in a net debt position of -575.15M. Total book value stands at 2.66B, with working capital of 1.10B providing operational flexibility.

Orient Pharma Co., Ltd. produced 127.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -60.05M in capital expenditures, free cash flow totaled 67.12M - equivalent to 0.28 per share.

Over the twelve months ended June 30, 2026, Orient Pharma Co., Ltd. posted a gross margin of 54.12, reflecting its pricing power and cost economics. The operating margin of 17.54 and net profit margin of 12.68 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Orient Pharma Co., Ltd. shareholders.

Orient Pharma Co., Ltd.'s most recent stock split took place on July 8, 2020 with a 703:761 split ratio.

As of June 30, 2026, Orient Pharma Co., Ltd. has an Altman Z-Score of 11.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.